Introduction to the Latest Research and Development Status and New Business in the Diagnostic Field
Bridge Biotherapeutics announced on the 7th that it conducted a corporate presentation for global pharmaceutical and bio industry stakeholders at the '2023 BIO International Convention (BIO USA),' held over four days from the 5th to the 8th of this month (local time) in Boston, USA.
Pavel Prinsev, Director of Business Development at Bridge Biotherapeutics, is presenting the company introduction at the 2023 BIO International Convention (BIO USA) held in Boston, USA, on the 6th (local time). [Photo by Bridge Biotherapeutics]
On the 6th, Bridge Biotherapeutics held a corporate introduction presentation targeting industry stakeholders and potential partners. Pavel Prinsev, Director of Business Development, who led the presentation, introduced the research and development pipeline focusing on key clinical-stage projects in the areas of lung cancer and pulmonary fibrosis. Additionally, the company unveiled its recently acquired diagnostic technologies on the global stage for the first time and shared its future growth vision and strategy.
Bridge Biotherapeutics is developing two clinical-stage lung cancer projects targeting the C797S mutation, which can arise as resistance after treatment with third-generation epidermal growth factor receptor (EGFR) inhibitors such as Tagrisso, widely used in non-small cell lung cancer therapy. The earlier-stage candidate 'BBT-176' is undergoing an expanded clinical phase 1 trial to prepare for phase 2 entry while simultaneously accumulating data to support global business development, the company explained. Alongside this, the company’s first independently discovered candidate, 'BBT-207,' recently received approval from the U.S. Food and Drug Administration (FDA) for an Investigational New Drug (IND) application to enter clinical phases 1/2.
In the field of idiopathic pulmonary fibrosis, the company is progressing with patient enrollment for a multinational phase 2 clinical trial of 'BBT-877' (an autotaxin inhibitor) and continuing development of candidates with different mechanisms tailored to disease characteristics caused by various factors, including 'BBT-301' (an ion channel modulator) and 'BBT-209' (a GPCR19 agonist).
Furthermore, the presentation also unveiled for the first time on the global stage the new business related to diagnostic technologies, which was accelerated by the acquisition of Ellips Diagnostics in April. The company stated that it is pursuing licensing negotiations with global companies based on the patent for the 'co-reactant,' a core component of its electrochemiluminescence (ECL) diagnostic technology that improves sensitivity and convenience over existing diagnostic methods.
Lee Jung-kyu, CEO of Bridge Biotherapeutics, said, "Following last year, we were able to widely promote the company’s business vision to global pharmaceutical and bio industry stakeholders at this year’s BIO USA and confirmed unprecedented high interest in our company." He added, "During the remaining days of the event, we plan to focus more on partnering meetings with various global pharmaceutical companies and other stakeholders and dedicate ourselves to achieving swift results."
BIO USA is the world’s largest pharmaceutical and bio industry partnering event, held in Boston, USA, known as the largest bio cluster globally. It is reported that more than 14,000 stakeholders from around the world attended.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
